Genetic signature and treatment of pediatric high-grade glioma

被引:4
|
作者
Guidi, Milena [1 ]
Giunti, Laura [2 ]
Buccoliero, Anna Maria [3 ]
Caporalini, Chiara [3 ]
Censullo, Maria Luigia [1 ]
Galli, Luisa [4 ]
Genitori, Lorenzo [5 ]
Sardi, Iacopo [1 ]
机构
[1] Meyer Childrens Univ Hosp, Neurooncol Unit, Dept Pediat Oncol, 24 Viale Gaetano Pieraccini, I-50139 Florence, Italy
[2] Meyer Childrens Univ Hosp, Med Genet Unit, I-50139 Florence, Italy
[3] Meyer Childrens Univ Hosp, Pathol Unit, I-50139 Florence, Italy
[4] Univ Florence, Dept Hlth Sci, I-50139 Florence, Italy
[5] Meyer Childrens Univ Hosp, Neurosurg Unit, I-50139 Florence, Italy
关键词
glioblastoma; high-grade glioma; histone; 3; midline glioma; oncology; pediatric; BRAF V600E;
D O I
10.3892/mco.2021.2232
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pediatric high-grade glioma (HGG) is a type of malignancy that carries a poor prognosis. The genetic analysis of HGGs has previously identified useful mutations, the targeting of which has improved prognosis. Thus, further research into the more common mutations, such as H3 histone variants (HIST1H3B and H3F3A) and BRAF V600E, may be useful in identifying tumors with different prognoses, as the mutations are considered to drive two distinct oncogenic programs. The present study performed a retrospective analysis of pediatric HGGs. In total, 42 cases of HGG, including 32 cases (76.1%) of anaplastic astrocytoma and 10 cases (23.8%) of glioblastoma multiforme (GBM), were assessed. The median age of the patients was 7 years (range, 0-32 years). Mutations on histone H3, in particular the K27M and G34R mutations in the distinct variants HIST1H3B and H3F3A, in addition to the presence of the BRAF V600E mutation, were analyzed in 24 patients. The H3F3A K27M mutation was identified in 7 patients (29.1%), while the HIST1H3B K27M mutation was only observed in 1 patient with GBM. In addition, 5 patients harbored a BRAF V600E mutation (21%), while the H3F3A G34R mutation was not recorded in any of the patients. The overall survival of the wild-type patients at 20 months was 68% [confidence interval (CI): 38-85%] compared with 28% (CI: 0.4-60%) in patients with the H3F3A K27M mutation. These results suggested that patients with the H3F3A K27M mutation had a worse prognosis compared with wild-type patients (P=0.0045). Moreover, 3/5 patients with the BRAF V600E mutation had HGGs that were derived from a previous low-grade glioma (LGG; P=0.001). In conclusion, these results suggested that histone H3 mutations may help predict the outcome in patients with HGG. In addition, the BRAF V600E mutation was found to be associated with an increased risk of anaplastic progression. The novel data of the present study may help better define the clinical and radiological characteristics of glioma.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [41] Response in pediatric high-grade glioma: What does it mean?
    Wolff, J. E. A.
    Wagner, S.
    Classen, C. F.
    Kortmann, R. D.
    Pietsch, T.
    Gnekow, A.
    [J]. NEURO-ONCOLOGY, 2006, 8 (04) : 308 - 309
  • [42] Cognitive awareness after treatment for high-grade glioma
    Giovagnoli, Anna Rita
    Meneses, Rute Flavia
    Paterlini, Chiara
    Silvani, Antonio
    Boiardi, Amerigo
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2021, 210
  • [43] Stereotactic Radiation Treatment in Recurrent High-grade Glioma
    Abazeed, M.
    Niemierko, A.
    Abazeed, A.
    Loefller, J. S.
    Oh, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S277 - S277
  • [44] HALOGENATED PYRIMIDINES AS RADIOSENSITIZERS IN THE TREATMENT OF HIGH-GRADE GLIOMA
    JACKSON, D
    KINSELLA, TJ
    WRIGHT, D
    KORNBLITH, P
    KATZ, D
    COLLINS, J
    ROWLAND, J
    GLATSTEIN, EJ
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (02): : 101 - 101
  • [45] Efficacy of Temozolomide Treatment in Patients with High-grade Glioma
    Oshiro, Shinya
    Tsugu, Hitoshi
    Komatsu, Fuminari
    Ohmura, Tadahiro
    Ohta, Mika
    Sakamoto, Seisaburou
    Fukushima, Takeo
    Inoue, Tooru
    [J]. ANTICANCER RESEARCH, 2009, 29 (03) : 911 - 917
  • [46] Fotemustine as a third line treatment of high-grade glioma
    Ramirez Daffos, P.
    Blanco Sanchez, G.
    Iglesias Lozano, I.
    Gomez Reina, M. J.
    Salguero Olid, A.
    Dominguez Lopez, M.
    Quilez Cutillas, A.
    Martinez Bautista, M. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S48 - S49
  • [47] EGFRVIII deletion mutations in pediatric high-grade glioma and response to erlotinib in pediatric glioma cell lines
    Bax, Dorine
    Gaspar, Nathalie
    Marshall, Lynley
    Little, Suzanne
    Regairaz, Marie
    Perryman, Lara
    Reis-Filho, Jorge
    Al-Sarraj, Safa
    Vassal, Gilles
    Pearson, Andrew
    Hargrave, Darren
    Workman, Paul
    Ellison, David
    Jones, Chris
    [J]. NEURO-ONCOLOGY, 2008, 10 (03) : 380 - 380
  • [48] Recurrent High-Grade Glioma
    Eudocia C. Quant
    Jan Drappatz
    Patrick Y. Wen
    Andrew D. Norden
    [J]. Current Treatment Options in Neurology, 2010, 12 : 321 - 333
  • [49] Pseudoprogression in high-grade glioma
    Knudsen-Baas, K. M.
    Moen, G.
    Fluge, O.
    Storstein, A.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 : 31 - 37
  • [50] Vincristine in High-grade Glioma
    Aydin, Burca
    Patil, Monali
    Bekele, Nebiyou
    Wolff, Johannes E. A.
    [J]. ANTICANCER RESEARCH, 2010, 30 (06) : 2303 - 2310